What is the Impact of Positive Airway Pressure in Nasal Polyposis? An Experimental Study
19 April 2018
06 October 2018
07 March 2019 (eFirst)
Introduction It has been hypothesized that increasing the interstitial hydrostatic pressure within the sinonasal mucosa of patients with nasal polyposis (NP) might decrease the size of nasal polyps.
Objective To evaluate the effects of positive airway pressure, delivered by a continuous positive airway pressure (CPAP) device, in patients with NP and in control subjects.
Methods Twelve patients with NP and 27 healthy subjects were exposed to CPAP (20 cm H2O) for 2 hours. Visual analog scale (VAS), Nasal Obstruction Symptom Evaluation (NOSE) scale, acoustic rhinometry (AR), peak nasal inspiratory flow (PNIF) and nasal endoscopy (NE—Meltzer polyp grading system) were performed before and after the intervention, for all patients.
Results The control group showed a significant worsening in nasal obstruction symptoms, as measured by VAS and NOSE (p < 0.01), and a significant decrease in nasal patency, as measured by the PNIF and AR (p < 0.01). For the NP group, VAS, NOSE, and AR did not differ significantly (p = 0.72, p = 0.73, and p = 0.17, respectively), but PNIF values worsened (p = 0.04) after exposure to CPAP. There was a statistically significant reduction in the nasal polyps' size (p = 0.04).
Conclusions Positive pressure worsened the nasal obstruction symptoms and decreased objective parameters of nasal patency in control subjects. In patients with NP, exposure to CPAP reduced the nasal polyps' size, and the nasal patency, as measured by PNIF. However, it had no significant effects in AR and in nasal obstruction symptoms.
- 1 Pezato R, Voegels RL, Pinto Bezerra TF, Perez-Novo C, Stamm AC, Gregorio LC. Mechanical disfunction in the mucosal oedema formation of patients with nasal polyps. Rhinology 2014; 52 (02) 162-166
- 2 Pezato R, Voegels RL, Stamm AC, Gregório LC. Why we should avoid using inferior turbinate tissue as control to Nasal Polyposis studies. Acta Otolaryngol 2016; 136 (09) 973-975
- 3 Pezato R, Voegels RL. Why do we not find polyps in the lungs? Bronchial mucosa as a model in the treatment of polyposis. Med Hypotheses 2012; 78 (04) 468-470
- 4 Gregório L, Pezato R, Felici RS, Kosugi EM. Fibrotic Tissue and Middle Turbinate Exhibit Similar Mechanical Properties. Is Fibrosis a Solution in Nasal Polyposis?. Int Arch Otorhinolaryngol 2017; 21 (02) 122-125
- 5 Fokkens WJ, Lund VJ, Mullol J. , et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50 (01) 1-12
- 6 Meltzer EO, Hamilos DL, Hadley JA. , et al; Rhinosinusitis Initiative. Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol 2006; 118 (5, Suppl): S17-S61
- 7 Bezerra TFP, Padua FGM, Pilan RRM, Stewart MG, Voegels RL. Cross-cultural adaptation and validation of a quality of life questionnaire: the Nasal Obstruction Symptom Evaluation questionnaire. Rhinology 2011; 49 (02) 227-231
- 8 Clement P a. R, Gordts F, Standardisation Committee on Objective Assessment of the Nasal Airway, IRS, and ERS. Consensus report on acoustic rhinometry and rhinomanometry. Rhinology 2005; ; Sep; 43 (03) 169-179
- 9 Suman JD. Current understanding of nasal morphology and physiology as a drug delivery target. Drug Deliv Transl Res 2013; 3 (01) 4-15
- 10 Liu Z, Gao Q, Zhang S, You X, Cui Y. Expression of tenascin and fibronectin in nasal polyps. J Huazhong Univ Sci Technolog Med Sci 2002; 22 (04) 371-374
- 11 Van Bruaene N, Derycke L, Perez-Novo CA. , et al. TGF-beta signaling and collagen deposition in chronic rhinosinusitis. J Allergy Clin Immunol 2009; 124 (02) 253-259 , 259.e1–259.e2
- 12 Li X, Meng J, Qiao X. , et al. Expression of TGF, matrix metalloproteinases, and tissue inhibitors in Chinese chronic rhinosinusitis. J Allergy Clin Immunol 2010; 125 (05) 1061-1068
- 13 Balsalobre L, Pezato R, Perez-Novo C. , et al. Epithelium and stroma from nasal polyp mucosa exhibits inverse expression of TGF-β1 as compared with healthy nasal mucosa. J Otolaryngol Head Neck Surg 2013; 42: 29
- 14 Figueiredo CR, Santos RP, Silva IDCG, Weckx LLM. Microarray cDNA to identify inflammatory genes in nasal polyposis. Am J Rhinol 2007; 21 (02) 231-235
- 15 Pezato R, de Almeida DC, Bezerra TF. , et al. Immunoregulatory effects of bone marrow-derived mesenchymal stem cells in the nasal polyp microenvironment. Mediators Inflamm 2014; 2014: 583409
- 16 Pezato R, Pérez-Novo CA, Holtappels G. , et al. The expression of dendritic cell subsets in severe chronic rhinosinusitis with nasal polyps is altered. Immunobiology 2014; 219 (09) 729-736
- 17 Perez-Novo C, Pezato R. Dendritic cell subset expression in severe chronic rhinosinusitis with nasal polyps. Curr Opin Allergy Clin Immunol 2017; 17 (01) 1-4
- 18 de Oliveira PWB, Pezato R, Agudelo JSH. , et al. Nasal Polyp-Derived Mesenchymal Stromal Cells Exhibit Lack of Immune-Associated Molecules and High Levels of Stem/Progenitor Cells Markers. Front Immunol 2017; 8: 39
- 19 Zozula R, Rosen R. Compliance with continuous positive airway pressure therapy: assessing and improving treatment outcomes. Curr Opin Pulm Med 2001; 7 (06) 391-398